Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Sanofi Pasteur
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A new vaccine for babies which adds protection against hepatitis B
To evaluate the concomitant administration of PR5I with two types of MCC vaccines (MCC-TT and MCC-CRM) to healthy infants at 3 and 4 months of age in term of antibody seroprotection rate (SPR) to MCC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine
To describe the Seroprotection rate (SPR) at least 2 years following completion of a primary series of modified process RECOMBIVAX HB™ ( HBVaxPRO) and 1 month following a challenge dose of modified pr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur Inc
MAJ Il y a 4 ans
A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI)
To compare the event rate of CDI in groups assigned to ACAM-CDIFF vaccine (pooled groups) versus placebo in the 9 week period after the third dose of study vaccine (Study Days 29 to 91) in subjects wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)
1) To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicina...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD
MAJ Il y a 4 ans
A phase 3 open-label study to evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I: hexavalent vaccine) at 2 and 6 months of age and Pediacel® (pentavalent vaccine) at 4 months of age Estudio abierto fase III para evaluar la respuesta inmune y la seguridad de un esquema de primovacunación que incluye V419 (PR5I: vacuna hexavalente) a los 2 y 6 meses de edad y Pediacel® (vacuna pentavalente) a los 4 meses de edad
The two co-primary objectives for the study are: -To demonstrate that the mixed schedule induces acceptable responses for Hepatitis B (% of subjects with an anti-HBs titre ≥10 mIU/mL ) one month after...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD SNC
MAJ Il y a 4 ans
An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age
The first primary objective is to demonstrate that a 2-dose regimen of ProQuad® rHA administered at a 3-month interval to healthy childrenof 11 months of age at the time of Dose 1 is as immunogenic ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur MSD S.N.C
MAJ Il y a 4 ans
A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to healthy infants at 2, 4 & 6 months of age followed by a booster dose at 12 months of age
1. To show, that when HEXAVAC® upgraded process is given in a 3-dose primary series at 2, 4 and 6 months of age, followed by a booster dose at 12 months the anti-HBs seroprotection rate one month post...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur Inc
MAJ Il y a 4 ans
Comparison of Pertussis Specific Cellular and Humoral Immunity Before and After a Acellular Pertussis Booster-Vaccineation in Combination With a Diphtheria-Tetanus-Polio-Vaccine Between Three Groups of Adolescents 10-14 Years of Age That Have Previously Either Received 4 or 5 Doses of Acellular Pertussis Vaccine or 4 Doses of of Whole-Cell Pertussis Vaccine
Evaluation of the pertussis-specific humoral and cellular immunity after vaccination with REPEVAX® or COVAXiS® or COVAXiS® + IPV Merieux® among three groups: Group A: Adolescents 10-14 years of age w...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur
MAJ Il y a 4 ans
Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Adult and Elderly Subjects
To demonstrate non-inferiority of antibody responses induced by QIV compared with the licensed 2011-2012 TIV (containing the B/Brisbane strain) and the investigational TIV (containing the B/Florida st...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Sanofi Pasteur SA
MAJ Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years
• To describe the immune response of each candidate vaccine 21 days after each vaccination by HAI and SN testing in all subjects. • To describe the safety profiles (injection site reactions, and syste...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
Suivant